Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
65 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07755397 | First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor | recruiting | Phase 1 | 30 | Jubilant Therapeutics India LimitedINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company Limited |
| 3 |
| Jul 28, 2026 |
| clinicaltrials |
| NCT07724873 | Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients | recruiting | Phase 1 / Phase 2 | 54 | Tata Memorial CentreOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | terminated | Phase 1 / Phase 2 | 124 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 10 | May 13, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05865002 | A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) | recruiting | Phase 1 | 50 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05984147 | A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)(ASHA-1) | recruiting | Phase 1 | 40 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06761586 | A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)(VIJAY-1) | terminated | Phase 1 | 9 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05570422 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 | recruiting | Phase 1 | 70 | Kortuc, Inc.INDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT05862012 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | recruiting | Phase 1 | 200 | Ichnos Sciences SAINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 369 | ImmunityBio, Inc.INDUSTRY | 3 | Mar 31, 2026 | clinicaltrials |
| NCT07436988 | Affordable Made-in-India Microspheres for Liver Cancer Therapy(ReLIVE) | not yet recruiting | Phase 1 | 18 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05478486 | Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours | completed | Phase 1 | 7 | Godavari Biorefineries LimitedOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06755450 | Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma(ADITI-1) | recruiting | Phase 1 | 40 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07138378 | A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.(XS003-11) | completed | Phase 1 | 128 | Xspray Pharma ABINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04480619 | Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients(Shiva) | not yet recruiting | Phase 1 / Phase 2 | 25 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Jul 16, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT05969314 | To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer | active not recruiting | Phase 1 | 12 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT05410002 | Diet Effect on Cancer Treatment Outcome | completed | Phase 1 | 160 | Optimal Health ResearchOTHER | 2 | Oct 3, 2024 | clinicaltrials |
| NCT05878691 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | active not recruiting | Phase 1 | 320 | Glenmark Specialty S.A.INDUSTRY | 2 | Jul 22, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT00667563 | Vaccine Therapy in Preventing HPV in HIV-Positive Women in India | completed | Phase 1 | 150 | AIDS Malignancy ConsortiumNETWORK | 1 | Mar 19, 2024 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT04942054 | A Study in Patients With Advanced Breast Cancer | terminated | Phase 1 | 9 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 2 | May 22, 2023 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT03638622 | Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.(UH3-India) | completed | Phase 1 / Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04332549 | To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT03681548 | A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. | completed | Phase 1 | 52 | Ayana Pharma Ltd.,INDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT02069704 | Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | completed | Phase 1 | 142 | mAbxience Research S.L.INDUSTRY | 5 | Jul 23, 2019 | clinicaltrials |
| NCT00862355 | Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02136927 | Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer | terminated | Phase 1 | 33 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT03109249 | Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 142 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT00864175 | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 68 | Incyte CorporationINDUSTRY | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00387387 | Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT02260544 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection | completed | Phase 1 | 49 | Dr. Reddy's Laboratories LimitedINDUSTRY | 1 | Sep 23, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT01118897 | Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers | completed | Phase 1 / Phase 2 | 60 | Tata Memorial HospitalOTHER_GOV | 1 | Aug 7, 2015 | clinicaltrials |
| NCT02492503 | Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix | unknown | Phase 1 / Phase 2 | 40 | All India Institute of Medical SciencesOTHER | 1 | Jul 8, 2015 | clinicaltrials |
| NCT01762410 | Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors | suspended | Phase 1 | 60 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials